Bristol-Myers Squibb (NYSE:BMY)'s CEO, Peter R. Dolan and General Counsel, Richard K. Willard, will be fired if the company's board of directors agrees with recommendations from an independent monitor. The Wall Street Journal made the unusual move of posting a "breaking news" notice on its web site in advance of the full story.
While Dolan's self-importance is such that the company's "about us" web page features his name, under "CEO:" as the first (and only managerial) Very Important Detail, he's made such gigantic missteps that a recent article said he had "precious little credibility." His attempts to delay generic competition for Plavix are being investigated by the Justice Department, and he's been responsible for "major financial scandals."
Today's Forbes asks, "Who Could Replace Peter Dolan?" and offers up names such as CFO Andrew Bonfield, Chief Scientific Officer Elliot Sigal (a "dark horse") and Karen Katen, Vice Chairman of Pfizer. We'll provide more details as we see them.
Heinz looking good after the second quarter?
Why isn't Bank of America updating its shareholders on CEO situation?
Will Rich Ross really have a positive impact on Disney's movie operations?
Reader Comments (Page 1 of 1)
9-12-2006 @ 3:29AM
Gary E. Sattler said...
I'll vote for Karen Katen.
Pfizer, right on the money.
End comment here.
Gary